PURPOSE: To evaluate satisfaction of acromegalic subjects with their medical treatment and its contribution to their quality of life. METHODS: This cross-sectional study included a total of 159 medications used in 133 subjects with acromegaly (controlled n = 84 and uncontrolled n = 49, female/male: 81/52). Subjects were asked to complete questionnaires on symptoms of depression (BDI) and satisfaction with the medical therapy they received for acromegaly (TSQM). Acromegaly cases also completed Acromegaly Quality of Life Questionnaire (AcroQoL). RESULTS: Subjects on pegvisomant therapy scored lower on convenience (p = 0.007). Cases on combination therapy had lower domain scores for effectiveness, convenience and global satisfaction in comparison to the cases on monotherapy (p = 0.01, p = 0.01 and p = 0.01, respectively). The time elapsed since diagnosis and the duration of medical therapy were positively correlated with effectiveness score (r = 0.2, p = 0.007 and r = 0.2, p = 0.04, respectively). The AcroQoL score was positively correlated with all domains of TSQM (for effectiveness r = 0.2, p = 0.01; for side effects r = 0.3, p = 0.001; for convenience r = 0.3, p = 0.004 and for global satisfaction r = 0.2, p = 0.01). In contrast, the BDI score was inversely correlated with all domains of TSQM (for effectiveness r = -0.3, p = 0.001; for side effects r = -0.2, p = 0.006; for convenience r = -0.3, p < 0.001 and for global satisfaction r = -0.3, p = 0.001). CONCLUSION: In acromegaly, quality of life, status of depression and satisfaction of the subjects with their treatment are intercorrelated.
PURPOSE: To evaluate satisfaction of acromegalic subjects with their medical treatment and its contribution to their quality of life. METHODS: This cross-sectional study included a total of 159 medications used in 133 subjects with acromegaly (controlled n = 84 and uncontrolled n = 49, female/male: 81/52). Subjects were asked to complete questionnaires on symptoms of depression (BDI) and satisfaction with the medical therapy they received for acromegaly (TSQM). Acromegaly cases also completed Acromegaly Quality of Life Questionnaire (AcroQoL). RESULTS: Subjects on pegvisomant therapy scored lower on convenience (p = 0.007). Cases on combination therapy had lower domain scores for effectiveness, convenience and global satisfaction in comparison to the cases on monotherapy (p = 0.01, p = 0.01 and p = 0.01, respectively). The time elapsed since diagnosis and the duration of medical therapy were positively correlated with effectiveness score (r = 0.2, p = 0.007 and r = 0.2, p = 0.04, respectively). The AcroQoL score was positively correlated with all domains of TSQM (for effectiveness r = 0.2, p = 0.01; for side effects r = 0.3, p = 0.001; for convenience r = 0.3, p = 0.004 and for global satisfaction r = 0.2, p = 0.01). In contrast, the BDI score was inversely correlated with all domains of TSQM (for effectiveness r = -0.3, p = 0.001; for side effects r = -0.2, p = 0.006; for convenience r = -0.3, p < 0.001 and for global satisfaction r = -0.3, p = 0.001). CONCLUSION: In acromegaly, quality of life, status of depression and satisfaction of the subjects with their treatment are intercorrelated.
Authors: Angela N Paisley; Susannah V Rowles; Margaret E Roberts; Susan M Webb; X Badia; L Prieto; Stephen M Shalet; Peter J Trainer Journal: Clin Endocrinol (Oxf) Date: 2007-06-06 Impact factor: 3.478
Authors: Jitske Tiemensma; Adrian A Kaptein; Alberto M Pereira; Johannes W A Smit; Johannes A Romijn; Nienke R Biermasz Journal: J Clin Endocrinol Metab Date: 2011-09-14 Impact factor: 5.958
Authors: Mark R Postma; Romana T Netea-Maier; Gerrit van den Berg; Jens Homan; Wim J Sluiter; Margreet A Wagenmakers; Alfons C M van den Bergh; Bruce H R Wolffenbuttel; Ad R M M Hermus; André P van Beek Journal: Eur J Endocrinol Date: 2012-01-16 Impact factor: 6.664
Authors: Susannah V Rowles; L Prieto; X Badia; Steven M Shalet; Susan M Webb; Peter J Trainer Journal: J Clin Endocrinol Metab Date: 2005-03-08 Impact factor: 5.958
Authors: Agatha A van der Klaauw; Nienke R Biermasz; Hendrieke C Hoftijzer; Alberto M Pereira; Johannes A Romijn Journal: Clin Endocrinol (Oxf) Date: 2008-07-01 Impact factor: 3.478
Authors: T Apaydin; H M Ozkaya; F E Keskin; O A Haliloglu; K Karababa; S Erdem; P Kadioglu Journal: J Endocrinol Invest Date: 2016-10-20 Impact factor: 4.256
Authors: A Giustina; G Arnaldi; F Bogazzi; S Cannavò; A Colao; L De Marinis; E De Menis; E Degli Uberti; F Giorgino; S Grottoli; A G Lania; P Maffei; R Pivonello; E Ghigo Journal: J Endocrinol Invest Date: 2017-02-07 Impact factor: 4.256
Authors: Victor J Geraedts; Cornelie D Andela; Günter K Stalla; Alberto M Pereira; Wouter R van Furth; Caroline Sievers; Nienke R Biermasz Journal: Front Endocrinol (Lausanne) Date: 2017-03-03 Impact factor: 5.555